Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
National Cancer Institute (NCI)
AIDS Malignancy Consortium
Jonsson Comprehensive Cancer Center
AIDS Malignancy Consortium
AIDS Malignancy Consortium
Latin American Cooperative Oncology Group
Peking Union Medical College Hospital
National Cancer Institute (NCI)
AIDS Malignancy Consortium
AIDS Malignancy Consortium
Hospitales Universitarios Virgen del Rocío
Chinese University of Hong Kong
National Institute of Allergy and Infectious Diseases (NIAID)
AIDS Malignancy Consortium
AIDS Malignancy Consortium
Jonsson Comprehensive Cancer Center
AIDS Malignancy Consortium
National Institutes of Health Clinical Center (CC)
Antiva Biosciences
Centre hospitalier de l'Université de Montréal (CHUM)
Antiva Biosciences
University Health Network, Toronto
National Institute of Allergy and Infectious Diseases (NIAID)
ANRS, Emerging Infectious Diseases
Southern California Institute for Research and Education
University Hospital, Geneva